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Abstract We have developed a technology for the profiling of miRNA expression in intact cells. The 
approach is based on sensor oligonucleotides, which upon entering the cell, bind specific miRNA targets, are 
cleaved as a result of this binding, and produce a fluorescent signal that is proportional to the abundance of 
the miRNA target. Specifically, the sensor oligonucleotides are completely complementary to a target 
miRNA species, are non-stabilized around the seed region (the region cleaved by the miRNA-RISC), and are 
labeled with a fluorescent dye and a quencher at their 5’- and 3’- end respectively. Upon entering the cell, 
these oligonucleotides engage the target miRNA by complementary base pairing. This leads to recruitment of 
the RNA induced silencing complex (RISC) to the duplex. The complex cleaves the sensor oligonucleotide 
and the miRNA is free to “catalyze” subsequent clevage reactions. The cleavage of the sensor oligo leads to 
separation between the dye and the quencher, and a resultant fluorescent enhancement that can be measured. 
We have demonstrated the feasibility of this method for the sensing of the pro-metastatic miRNA-10b in 
cell-free extracts and intact cells using human and murine breast adenocarcinoma cell lines. 
The miRNA epigenome represents a fundamental molecular regulator of metastasis. Consequently, 
developing tools to understand metastatic changes at the miRNA level can lead to the mapping out of a 
comprehensive and systematic atlas of cancer progression. The described technology is potentially 
transformative because it addresses this important issue. Furthermore, the technology has broad implications 
and can be utilized in any model system or clinical scenario to answer questions related to microRNA 
function. Specifically, the technology can help distinguish, assess, and/or monitor cancer stages and 
progression; aid the elucidation of basic mechanisms underlying cancer initiation and progression; facilitate 
early cancer detection and/or cancer risk assessment; and facilitate/accelerate the process of drug discovery. 
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1. Introduction  
 During the past decade, over 25,000 
papers deposited on PubMed have reported 
on various aspects of miRNA genomics, 
biogenesis, mechanisms of action, pathway 
involvement, phenotypes in experimental 
models and disease abnormalities. About 
40% of these publications have focused on 
the role of miRNAs in cancer. These studies 
have shown that miRNAs are dysregulated 
in almost all types of human cancer and 
specific signatures of aberrantly expressed 
miRNAs harbour diagnostic, prognostic and 
theranostic implications, including early 
diagnosis and staging, discrimination 
between different types of cancer, the 
identification of the tissue of origin of 
poorly differentiated tumors, prediction of 
chemotherapeutic response, etc. These are 
all challenges that are still largely 
unresolved and the subject of intense clinical 
interest.  
 Overwhelming evidence in the 
literature indicates that miRNAs are 
excellent biomarkers for any of these 
processes (Ling et al., 2013). Consequently, 
developing tools to understand how 
miRNAs participate in key aspects of 
carcinogenesis can lead to the mapping out 
of a comprehensive and systematic atlas of 
cancer progression.  
 Cinically, we envision a variety of 
scenarios that could benefit from the ability 
to profile miRNA exression. For example, it 
is now known that miR-10b is upregulated 
in the tumors of patients who harbor 
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metastatic disease, indicating that miR-10b 
could be used to diagnose the presence of 
metastasis or even to forecast invasive 
disease (Baffa et al., 2009; Chen et al., 2013; 
Iyevleva et al., 2012). The ability to detect 
miR-10b upregulation in the primary tumors 
by noninvasive or laparoscopic methods that 
specifically target a suspected lesion would 
be very clinically important. miR-10b and -
155 are also part of a panel of miRNAs that 
demonstrate aberrant expression in tissue 
from patients with triple negative breast 
cancer that displays chemoresistance 
(Ouyang et al., 2014). In this context, 
noninvasive or laparoscopic imaging can 
help guide therapeutic decisions.  
 With the goal of making such 
diagnostics possible, we have developed 
technology for the profiling of tumor 
miRNAs in intact cells. The technology is 
based on sensors capable of reporting on 
miRNA expression. It is described in detail 
in (Yoo et al., 2014). In our studies, we have 
focused on a miRNA involved in the early 
stages of breast cancer metastasis. However, 
the developed methodology can be applied 
broadly to study miRNA regulation of any 
process related to carcinogenesis and 
response to therapy.  
 The technology is significant 
because it allows one to profile tumor 
miRNA signatures in intact cells. This is 
important because it is only through such 
studies that one can capture the true 
dynamics of molecular processes. Since the 
method is noninvasive to the cell, it will 
ultimately be possible to collect time-course 
data in genuine cellular environments and 
thus gain a better understanding of long-term 
trends.   
 In a laboratory setting, this new 
capability holds potential to:  
1. help distinguish, assess, and/or monitor 
cancer stages and progression;  
2. aid the elucidation of basic mechanisms 
underlying cancer initiation and progression.  
 The technology also has clinical 
relevance. The sensors can be delivered in 
vivo by conjugating them to a carrier. 
Consequently, a derivative of the developed 
technology may ultimately become 
applicable in a clinical setting and as such 
has the potential of significantly advancing 
our ability to diagnose and treat breast 
cancer. The clinical feasibility of the method 
is underscored further by the fact that optical 
imaging methods have already been applied 
for clinical breast imaging (Manohar et al., 
2007; Poellinger et al., 2008; Soliman et al.; 
van de Ven et al., 2009). Alternatively, one 
can envision a utility for our method using 
laparoscopic or intraoperative diagnostics. 
 In a clinical setting, the technology 
could:  
1. facilitate early cancer detection and/or 
cancer risk assessment; and  
2. facilitate/accelerate the process of drug 
discovery.  
 
2. The sensor can report on individual 
miRNA expression with high sensitivity 
and specificity (cell-free system) (Yoo et 
al., 2014).   
 To assess the feasibility of the 
proposed approach, we performed a study in 
which we designed a cleavable sensor oligo 
to detect miR-10b expression. MiR-10b has 
been implicated in epithelial to 
mesenchymal transition and breast cancer 
metastasis by multiple studies including by 
our own group (Yigit et al., 2013)
,
 (Baffa et 
al., 2009; Ma et al., 2010; Ma et al., 2007). 
Considering that the focus of the application 
is to profile the expression of pro-metastatic 
miRNAs in breast tumor cells, we targeted 
miRNA-10b in our studies. Specifically, we 
designed an RNA sensor oligonucleotide 
that was completely complementary to the 
miRNA-10b seed region and was conjugated 
to a Cy5 dye at the 5’ end and Iowa Black 
RQ quencher at the 3’ end separated by 22 
nucleotides (7.5 nm). Its sequence was: AC 
AAA UUC GGU UCU ACA GGG UA. 
First we determined the signal-to-
background ratio by incubating 100nM of 
the sensor oligo with a 10g/ml of nuclease. 
Cleavage of the oligo resulted in a 566% 
fluorescence enhancement after de-
quenching compared to the noncleaved oligo 
incubated in RNase-free conditions. 
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 To determine the sensitivity and 
specificity of detection, we designed a cell-
free assay, based on Refs (Brown et al., 
2005; Robb et al., 2005). Studies were 
performed in the metastatic human breast 
cancer cell line MDA-MB-231-luc-D3H2LN 
(Caliper Life Sciences, Hopkinton, MA). 
Briefly, the cells were lysed and cytoplasmic 
extracts prepared, as described in (Brown et 
al., 2005; Robb et al., 2005) Half of the 
extracts were incubated with a 10-fold 
excess of anti-miR10b locked nucleic acid 
(LNA) antisense oligonucleotides to miR-
10b (ASO, Exiqon, Woburn, MA). LNA 
modification prevents these ASO from 
cleavage by miRNA and instead leads to 
inhibition of miRNA function (termed miR-
10b-depleted control). The second half of 
the cell extracts was incubated with 
irrelevant oligo (SCR ASO), which does not 
bind miR-10b or any other of the annotated 
miRNAs and leaves miR-10b active. 
 Following, the miR-10b sensor 
oligo was titrated into the miR-10b-depleted 
and miR-10b-active extracts Fluorescence 
from the sensor oligo was then recorded 
using epifluorescence optical imaging (Ivis 
Spectrum, 649 nm excitation; 670nm 
emission).  
 There was distinctive fluorescence 
enhancement with increased concentration 
of the sensor oligo in the extracts in which 
miR-10b was active after treatment with 
irrelevant oligo (SCR ASO). On the 
contrary, the extracts in which miRNA-10b 
was depleted (inhibited) by incubation with 
miR-10b ASO the signal was significantly 
lower. Using linear regression analysis, we 
calculated a detection limit of 13.4nM. 
 Finally, we confirmed cleavage of 
the sensor oligo by miR-10b-RISC using gel 
electrophoresis. This indicated that the 
observed fluorescence enhancement is the 
result of cleavage of the sensor oligo and 
confirmed that miR-10b can mediate 
cleavage of the substrate oligo as designed, 
despite the fact that none of its known 
mRNA targets are regulated by cleavage. 
Electrophoresis was performed as described 
in (Brown et al., 2005; Robb et al., 2005).  
3. The sensor can report on miRNA 
expression in intact cells (Yoo et al., 2014). 
 To test the hypothesis that the 
sensor as designed will be capable of 
reporting on miRNA expression in intact 
cells, we incubated MDA-MB-231-luc-
D3H2LN cells with miR-10b-specific sensor 
at concentrations ranging from 25 to 
1000nM. MiR-10b depleted cells obtained 
by inhibiting miR-10b with ASO (using 
lipofectamine transfection) served as 
control. There was a significant difference in 
fluorescence intensity between the cells 
treated with the sensor specific to miR-10b 
and the miR-10b-depleted control cells 
(p<0.05). These differences were 
independent of sensor concentration above 
250nM.  
 To estimate the rate of sensor “turn-
on” we performed a time course study at 
fixed sensor concentration of 125 nM. 
Maximum fluorescence intensity was 
reached within 16 hrs. In control cells 
depleted of miR-10b, the rate of sensor 
cleavage (non specific) was low and, even 
after 48 hrs of incubation, the fluorescence 
intensity did not reach maximum.  
 Fluorescence microscopy revealed 
that cells could easily be delineated based on 
fluorescence from the sensor. Finally, as an 
illustration of a related application, flow 
cytometry was used to compare cells treated 
with sensor alone or pretreated with the 
ASO. That experiment confirmed our 
observations using epifluorescence that the 
approach could quantitatively reflect 
differences in miRNA expression. 
Irrespective of the method used (flow 
cytometry or epifluorescence), the miRNA 
expression as measured by our approach was 
accurate because it fell within one standard 
deviation of that measured by the gold-
standard qRT-PCR.  
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4. In vivo application 
 The in vivo applicability of the 
sensor derives from a nanodelivery vector 
described extensively in our prior 
publications [Kumar, 2011 #30; Medarova, 
2007 #29; Yigit, 2013 #34]. Specifically, we 
have developed nanoparticles that 
accumulate in tumor cells, following 
intravenous injection. Upon internalization 
of the nanoparticles by the cell, the 
nanoparticles efficiently engage the 
endogenous cytosolic RNA interference 
apparatus in a sequence-specific way.  
 The nanoparticles consist of 
dextran-coated iron oxide crystals (MN, 25-
30 nm in diameter), conjugated to sensor 
oligos that are complementary to 
endogenous miRNA species (Fig. 1A).  
These sensor oligonucleotides are composed 
of RNA bases, are cleavable (non-stabilized 
by chemical modification) around the seed 
region (the conserved region within which 
the microRNA engages the RNA substrate), 
and are labeled with a fluorescent dye-
quencher pair, so that upon cleavage of the 
oligonucleotide by the microRNA-RISC, 
there is fluorescence enhancement (Fig. 1A).  
 The proposed mechanism is 
described in Fig. 1B. Namely, the 
nanoparticles are endocytosed (Fig. 1BI and 
BII) by the tumor cells and localize to 
endosomes (Fig. 1BIII). Inside endosomes, 
the functionalized nanoparticles rich in 
unsaturated amines mediate the proton 
sponge effect by sequestering protons that 
are supplied by the v-ATPase (proton 
pump). This process keeps the pump 
functioning and leads to the retention of one 
Cl- ion and one water molecule per proton. 
Subsequent endosomal swelling and rupture 
leads to particle deposition in the cytoplasm 
(Fig. 1BIV) 31.  
 In the cytosol, the nanoparticles, 
which carry a sensor oligo complementary to 
an endogenous microRNA species, bind the 
microRNA (Fig. 1BV), leading to the 
recruitment to the duplex of the endogenous 
RNA induced silencing complex (RISC) and 
cleavage of the oligo at a specific position in 
the seed region (Fig. 1BVI). This cleavage 
results in separation between the quencher 
and dye located at the ends of the sensor 
oligo, and fluorescent turn-on. The 
microRNA is released from the complex and 
 
Fig. 1. Nanosensor design (A) and mechanism of action (B). 
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is free to catalyze subsequent cleavage 
reactions (Fig. 1BVII).  
 The described mechanism exploits 
the endogenous process of RNA interference 
and takes advantage of powerful signal 
amplification, since millions of 
nanoparticles/oligos are delivered per cell, 
using our delivery method. 
 The in vitro studies are described in 
detail in our recent publication (Yoo et al., 
2014). They indicate that the nanosensor 
design for in vivo application is feasible and 
lay the groundwork for in vivo pre-clinical 
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